Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same
US6979546B2 · kind B2 · utility
8Cited by
1References
11Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 7, 2002 |
| Grant date | Dec 27, 2005 |
| Priority date | — |
| Expiry date | Oct 25, 2022 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/809
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a novel compound termed NKp30 that is selectively expressed by all mature NK cells and that is involved in human natural cytoxicity as an activatory receptor, to new antibodies that bind to the NKp30 structure, and to the pharmaceutical and medicinal uses thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.